Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.

@article{Saad2008RisksAB,
  title={Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.},
  author={Amr Ahmed Saad and Deborah P M Symmons and Peter R. Noyce and Darren M Ashcroft},
  journal={The Journal of rheumatology},
  year={2008},
  volume={35 5},
  pages={
          883-90
        }
}
OBJECTIVE To evaluate the efficacy and safety of tumor necrosis factor-alpha (TNF-alpha) inhibitors in the management of psoriatic arthritis (PsA). METHODS We searched electronic databases to identify randomized controlled trials (RCT) of adalimumab, etanercept, and infliximab used in patients with PsA. Random effects metaanalysis was undertaken to produce pooled estimates of the relative risk, risk difference, or the weighted mean difference for efficacy and safety outcomes using Stata… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 59 CITATIONS

FILTER CITATIONS BY YEAR

2008
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.

Risks and benefits of tumor necrosis factor - alpha inhibitors in the management of psoriatic arthritis : systematic review and metaanalysis of randomized controlled trials

  • P SymmonsD, P Noyce, M AshcroftD

Similar Papers

Loading similar papers…